BioLife Solutions Inc 2026年季度报告

FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended March 31, 2026 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGEACT OF 1934For the transition period fromto Commission File Number 001-36362 BioLife Solutions, Inc.(Exact name of registrant as specified in its charter) 94-3076866(IRS EmployerIdentification No.) 3303 Monte Villa Parkway, Suite 310, Bothell, Washington, 98021(Address of registrant’s principal executive offices, Zip Code) (425) 402-1400(Telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Actof 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has beensubject to such filing requirements for the past 90 days. YesNo Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule405 of Regulation S-T (S232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required tosubmit said files). YesNo Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reportingcompany or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company” and“emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filerAccelerated filerNon-accelerated filerSmaller reporting companyEmerging Growth Company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complyingwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). YesNo As of April30, 2026, 48,857,415 shares of the registrant’s common stock were outstanding. BIOLIFE SOLUTIONS, INC. FORM 10-Q FOR THE QUARTER ENDED MARCH 31, 2026 TABLE OF CONTENTS PART I. FINANCIAL INFORMATION 3Item 1.Unaudited Condensed Consolidated Financial Statements3Unaudited Condensed Consolidated Balance Sheets as of March 31, 2026and December 31, 20254Unaudited Condensed Consolidated Statements of Operations for the three months ended March 31, 2026 and 20255Unaudited Condensed Consolidated Statements of Comprehensive Income (Loss) for the three months ended March31, 2026 and 20256Unaudited Condensed Consolidated Statements of Shareholders’ Equity for the three months ended March 31, 2026and 20257Unaudited Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2026 and 20258Notes to Unaudited Condensed Consolidated Financial Statements10Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations30Item 3.Quantitative and Qualitative Disclosures about Market Risk35Item 4.Controls and Procedures35PART II. OTHER INFORMATION36Item 1.Legal Proceedings36Item 1A.Risk Factors36Item 2.Unregistered Sales of Equity Securities and Use of Proceeds36Item 3.Defaults Upon Senior Securities36Item 4.Mine Safety Disclosures36Item 5.Other Information36Item 6.Exhibits37Signatures38 Table of Contents PART I. FINANCIAL INFORMATION Item1.Financial Statements BioLife Solutions, Inc.Unaudited Condensed Consolidated Statements of Operations BioLife Solutions, Inc.Unaudited Condensed Consolidated Statements of Cash Flows BioLife Solutions, Inc.Notes to Unaudited Condensed Consolidated Financial Statements 1.Organization and significant accounting policies Business BioLife Solutions, Inc. (“BioLife”, “us”, “we”, “our”, or the “Company”) is a life sciences company that develops, manufactures, and marketsbioproduction products and services which are designed to improve quality and de-risk biologic manufacturing, distribution, and transportationin the cell and gene therapy ("CGT") industry. Our products are used in basic and applied research and commercial manufacturing of biologic-based therapies. Customers use our products to maintain the health and function of biologic material during sourcing, manufacturing, anddistribution. Our products include proprietary biopreservation media, human platelet lysate media (“hPL”), cryogenic vials, automated cell-processing fill machines, and automated thawing devices. Our CryoStor® freeze media and HypoThermosol® hypothermic storage media areoptimized to preserve cells in the regenerative medicine market. These novel biopreservation media products are serum-free and protein-free,fully defined, and formulated to reduce preservation-induced cell damage and death. Our Sexton cell processing product